Anidulafungin for the treatment of invasive candidiasis

Clinical Microbiology and Infection

Volumn 17, Issue , 2011, Pages 1-12

  Mayr, A ^a   Aigner, M ^a   Lass Florl C ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anidulafungin; candidaemia; critically ill patients; echinocandins; invasive candidiasis

Indexed keywords

EID: 85020530537     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03448.x     Document Type: Article

References (94)

1. Hsueh, PR., Graybill, JR., Playford, EG, et al. Consensus statement on the management of invasive candidiasis in intensive care units in the Asia-Pacific Region. Int J Antimicrob Agents 34 (2009), 205–209.
2. Bouza, E., Muñoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 32:suppl 2 (2008), S87–S91.
3. Bassetti, M., Ansaldi, F., Nicolini, L, et al. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother 64 (2009), 625–629.
4. De Rosa, FG., Garazzino, S., Pasero, D., Di Perri, G., Ranieri, VM., Invasive candidiasis and candidemia: new guidelines. Minerva Anestesiol 75 (2009), 453–458.
5. Guery, BP., Arendrup, MC., Auzinger, G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis. Intensive Care Med 35 (2009), 55–62.
6. Horn, DL., Neofytos, D., Anaissie, EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48 (2009), 1695–1703.
7. Pappas, PG., Kauffman, CA., Andes, D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48 (2009), 503–535.
8. Lass-Flörl, C., The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52 (2009), 197–205.
9. Concia, E., Azzini, AM., Conti, M., Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients. Drugs 69:suppl 1 (2009), 5–14.
10. Wisplinghoff, H., Bischoff, T., Tallent, SM., Seifert, H., Wenzel, RP., Edmond, MB., Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004), 309–317.
11. Tortorano, AM., Kibbler, C., Peman, J., Bernhardt, H., Klingspor, L., Grillot, R., Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 27 (2006), 359–366.
12. Tortorano, AM., Peman, J., Bernhardt, H, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23 (2004), 317–322.
13. Pfaller, MA., Diekema, DJ., Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20 (2007), 133–163.
14. Almirante, B., Rodríguez, D, Park, BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43 (2005), 1829–1835.
15. Arendrup, MC., Fuursted, K., Gahrn-Hansen, B, et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 43 (2005), 4434–4440.
16. Asmundsdóttir, LR, Erlendsdóttir, H, Gottfredsson, M., Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 40 (2002), 3489–3492.
17. Poikonen, E., Lyytikäinen, O, Anttila, VJ., Ruutu, P., Candidemia in Finland, 1995–1999. Emerg Infect Dis 9 (2003), 985–990.
18. Sandven, P., Bevanger, L., Digranes, A, et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 44 (2006), 1977–1981.
19. Silveira, FP., Husain, S., Fungal infections in solid organ transplantation. Med Mycol 45 (2007), 305–320.
20. Eggimann, P., Garbino, J., Pittet, D., Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3 (2003), 685–702.
21. Leroy, O., Gangneux, JP., Montravers, P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med 37 (2009), 1612–1618.
22. Bougnoux, ME., Kac, G., Aegerter, P., d'Enfert, C., Fagon, JY., CandiRea Study Group. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 34 (2008), 292–299.
23. Hassan, I., Powell, G., Sidhu, M., Hart, WM., Denning, DW., Excess mortality, length of stay and cost attributable to candidaemia. J Infect 59 (2009), 360–365.
24. Gudlaugsson, O., Gillespie, S., Lee, K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37 (2003), 1172–1177.
25. Gagne, JJ., Goldfarb, NI., Candidemia in the in-patient setting: treatment options and economics. Expert Opin Pharmacother 8 (2007), 1643–1650.
26. Gagne, JJ., Breitbart, RE., Maio, V, et al. Costs associated with candidemia in a hospital setting. Pharmacol Ther 31 (2006), 586–619.
27. Zaoutis, TE., Argon, J., Chu, J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41 (2005), 1232–1239.
28. Rentz, AM., Halpern, MT., Bowden, R., The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 27 (1998), 781–788.
29. Pfaller, MA., Boyken, L., Hollis, RJ., Messer, SA., Tendolkar, S., Diekema, DJ., In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 43 (2005), 5425–5427.
30. Pfaller, MA., Diekema, DJ., Rinaldi, MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 43 (2005), 5848–5859.
31. Pereira, GH., Müller, PR, Szeszs, MW., Levin, AS., Melhem, MS., Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans Candida species. Med Mycol 48 (2010), 839–842.
32. Lewis, RE., Overview of the changing epidemiology of candidemia. Curr Med Res Opin 25 (2009), 1732–1740.
33. Messer, SA., Jones, RN., Fritsche, TR., International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 44 (2006), 1782–1787.
34. Taur, Y., Cohen, N., Dubnow, S., Paskovaty, A., Seo, SK., The effect of antifungal timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 54 (2010), 184–190.
35. Parkins, MD., Sabuda, DM., Elsayed, S., Laupland, KB., Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 60 (2007), 613–618.
36. Morrell, M., Fraser, VJ., Kollef, MH., Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49 (2005), 3640–3645.
37. Garey, KW., Rege, M., Pai, MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43 (2006), 25–31.
38. Shorr, AF., Tabak, YP., Johannes, RS., Sun, X., Spalding, J., Kollef, MH., Candidemia on presentation to the hospital: development and validation of a risk score. Crit Care, 13, 2009, R156.
39. Cruciani, M., de Lalla, F., Mengoli, C., Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 31 (2005), 1479–1487.
40. Lam, SW., Eschenauer, GA., Carver, PL., Evolving role of early antifungals in the adult intensive care unit. Crit Care Med 37 (2009), 1580–1593.
41. Rotstein, C., Invasive candidiasis in the ICU: prophylaxis versus preemptive treatment. Curr Infect Dis Rep 10 (2008), 454–458.
42. Guery, BP., Arendrup, MC., Auzinger, G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part II. Treatment. Intensive Care Med 35 (2009), 206–214.
43. Viscoli, C., Antifungal prophylaxis and pre-emptive therapy. Drugs 69:suppl 1 (2009), 75–78.
44. Charles, PE., Castro, C., Ruiz-Santana, S., León, C, Saavedra, P., Martín E. Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis. Intensive Care Med 35 (2009), 2146–2150.
45. León, C, Ruiz-Santana, S., Saavedra, P, et al. Usefulness of the ‘Candida score’ for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37 (2009), 1624–1633.
46. Khot, PD., Fredricks, DN., PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther 7 (2009), 1201–1221.
47. Pemán, J, Zaragoza, R., Current diagnostic approaches to invasive candidiasis in critical care settings. Mycoses 53 (2010), 424–433.
48. Schuster, MG., Edwards, JE Jr, Sobel, JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 149 (2008), 83–90.
49. European Medicines Agency. Ecalta—product information. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000788/human_med_000751.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 (last accessed 22 November 2010).
50. European Medicines Agency. Mycamine—product information. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000734/human_med_000911.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 (last accessed 22 November 2011).
51. European Medicines Agency. Cancidas—product information. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000379/human_med_000684.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 (last accessed 22 November 2010).
52. European Medicines Agency. Vfend—product information. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000387/human_med_001135.jsp&murl=menus/medicines/medicines.jsp (last accessed 22 November 2010).
53. European Medicines Agency. Noxafil—product information. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000610/human_med_000937.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 (last accessed 22 November 2010).
54. Abelcet–summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/2133/SPC/Abelcet/ (last accessed 22 November 2010).
55. Ambisome—summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/1236/SPC/AmBisome/ (last accessed 22 November 2010).
56. Diflucan—summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/1459/SPC/Diflucan+Capsules+50mg+and+200mg%2c+Powder+for+Oral+Suspension++50mg+5ml+and+200mg+5ml%2c++Intravenous+Infusion+2mg+ml/ (last accessed 22 November 2010).
57. Fungizone—summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/559/SPC/Fungizone/ (last accessed 22 November 2010).
58. Morace, G., Borghi, E., Iatta, R., Montagna, MT., Anidulafungin, a new echinocandin: in vitro activity. Drugs 69:suppl 1 (2009), 91–94.
59. Diekema, DJ., Messer, SA., Boyken, LB, et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol 47 (2009), 3170–3177.
60. Pfaller, MA., Boyken, L., Hollis, RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46 (2008), 150–156.
61. Cuenca-Estrella, M., Mellado, E., Díaz-Guerra, TM., Monzón, A, Rodríguez-Tudela, JL., Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother 46 (2000), 475–477.
62. Reboli, AC., Rotstein, C., Pappas, PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356 (2007), 2472–2482.
63. Cappelletty, D., Eiselstein-McKitrick, K., The echinocandins. Pharmacotherapy 27 (2007), 369–388.
64. Pfaller, MA., Boyken, L., Hollis, RJ., Messer, SA., Tendolkar, S., Diekema, DJ., In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 44 (2006), 760–763.
65. Ghannoum, MA., Chen, A., Buhari, M, et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect 15 (2009), 274–279.
66. Walsh, TJ., Echinocandins–an advance in the primary treatment of invasive candidiasis. N Engl J Med 347 (2002), 2070–2072.
67. Bennett, JE., Echinocandins for candidemia in adults without neutropenia. N Engl J Med 355 (2006), 1154–1159.
68. Pfaller, MA., Diekema, DJ., Ostrosky-Zeichner, L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 46 (2008), 2620–2629.
69. Pfaller, MA., Diekema, DJ., Boyken, L, et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother 49 (2005), 4795–4797.
70. Horn, DL., Ostrosky-Zeichner, L., Morris, MI, et al. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis 29 (2010), 223–229.
71. Jacobson, MJ., Piper, KE., Nguyen, G., Steckelberg, JM., Patel, R., In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother 52 (2008), 2242–2243.
72. Katragkou, A., Chatzimoschou, A., Simitsopoulou, M, et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother 52 (2008), 357–360.
73. Ernst, EJ., Klepser, ME., Pfaller, MA., Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 44 (2000), 1108–1111.
74. Chamilos, G., Lewis, RE., Albert, N., Kontoyiannis, DP., Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 5 (2007), 2257–2259.
75. Fleischhacker, M., Radecke, C., Schulz, B., Ruhnke, M., Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 27 (2008), 127–131.
76. Dowell, JA., Knebel, W., Ludden, T., Stogniew, M., Krause, D., Henkel, T., Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 44 (2004), 590–598.
77. European Medicines Agency. Ecalta—scientific discussion, 2007. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000788/human_med_000751.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 (last accessed 22 November 2010).
78. Damle, BD., Dowell, JA., Walsky, RL., Weber, GL., Stogniew, M., Inskeep, PB., In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother 53 (2009), 1149–1156.
79. Dowell, JA., Stogniew, M., Krause, D., Damle, B., Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 47 (2007), 461–470.
80. Borges, Sá M, Garnacho, Montero J., Role of anidulafungin in critically ill patients. Enferm Infecc Microbiol Clin 26:suppl 14 (2008), 35–43.
81. Wagner, C., Graninger, W., Presterl, E., Joukhadar, C., The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 78 (2006), 161–177.
82. Vehreschild, JJ., Kümmerle, T, Karthaus, M., Cornely, OA., Anidulafungin—state of affairs from a clinical perspective. Mycoses 50:suppl 1 (2007), 38–43.
83. Krause, DS., Reinhardt, J., Vazquez, JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 48 (2004), 2021–2024.
84. Mora-Duarte, J., Betts, R., Rotstein, C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002), 2020–2029.
85. Kuse, ER., Chetchotisakd, P., da Cunha, CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 (2007), 1519–1527.
86. Dupont, BF., Lortholary, O., Ostrosky-Zeichner, L., Stucker, F., Yeldandi, V., Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care, 13, 2009, R159.
87. Reboli, AC., Rotsteinm, C., Kett, DH, et al. Resource utilisation and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. Pharmacoeconomics, [in press].
88. Nolla-Salas, J., Sitges-Serra, A., León-Gil, C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 23 (1997), 23–30.
89. Gafter-Gvili, A., Vidal, L., Goldberg, E., Leibovici, L., Paul, M., Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 83 (2008), 1011–1021.
90. Kett, DH., Shorr, AF., Reboli, AC., Reisman, AL., Biswas, P., Schlamm, HT., Anidulafungin compared with fluconazole therapy in critically ill patients. Crit Care, 14(suppl 1), 2010, P72.
91. Benjamin, DK Jr, Driscoll, T., Seibel, NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 50 (2006), 632–638.
92. Brielmaier, BD., Casabar, E., Kurtzeborn, CM., McKinnon, PS., Ritchie, DJ., Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacotherapy 28 (2008), 64–73.
93. Maertens, J., Marchetti, O., Herbrecht, R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 Update. Bone Marrow Transplant, 2010 Jul 26. [Epub ahead of print].
94. Burkhardt, O., Kaever, V., Burhenne, H., Kielstein, JT., Extended daily dialysis does not affect the pharmacokinetics of anidulafungin. Int J Antimicrob Agents 34 (2009), 282–283.